Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sentinel Lymph Node Mapping & Metastasis

Gynecol Oncol; ePub 2016 Feb 18; Holloway, et al

The addition of sentinel lymph node mapping (SLN) with staging lymphadenectomy more than doubled the detection of lymph node metastasis compared to pelvic lymphadenectomy alone in patients with endometrial cancer and was also associated with increased use of adjuvant therapies. This according to a study of 780 patients with apparent early-stage endometrial cancer. Researchers found:

• The mapped group had more pelvic lymph node (LN) harvested compared to the non-mapped group (26.4 vs 18.8).

• Aortic LN yields were identical for both groups.

• The mapped group had more LN metastasis detected (30.3% vs 14.7%), more stage IIIC (30.2% vs 14.5%), more GOG high-risk cases (32.8% vs 21.8%), and received more chemotherapy + radiation (28.6% vs 16.3%).

• The SLN was the only metastasis in 18 (50%) mapped cases with positive modes.

• The SLN false negative rate was 2.8%.

Citation: Holloway RW, Gupta S, Stavitzski NM , et al. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. [Published online ahead of print February 18, 2016]. Gynecol Oncol. doi:http://dx.doi.org/10.1016/j.ygyno.2016.02.018.